Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Robert F SpieraSebastian UnizonyKenneth J WarringtonJennifer SloaneAngeliki GiannelouMichael C NivensBolanle AkinladeWanling WongRafia BhoreYong LinFrank ButtgereitValerie Devauchelle-PensecAndrea Rubbert-RothGeorge D YancopoulosFrederic MarracheNaimish PatelBhaskar Dasguptanull null

Published in: The New England journal of medicine (2023)

Sarilumab showed significant efficacy in achieving sustained remission and reducing the cumulative glucocorticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering. (Funded by Sanofi and Regeneron Pharmaceuticals; SAPHYR ClinicalTrials.gov number, NCT03600818.).

Keyphrases

giant cell
free survival
disease activity